Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
17 hedge funds and large institutions have $71.7M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 10 closing their positions.
23% less funds holding
Funds holding: 22 → 17 (-5)
50% less capital invested
Capital invested by funds: $143M → $71.7M (-$71.1M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$445K |
| 3 |
BlackRock
New York
|
+$179K |
| 4 |
Renaissance Technologies
New York
|
+$104K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$6.62M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.96M |
| 3 |
O
OrbiMed
New York
|
-$1.86M |
| 4 |
Millennium Management
New York
|
-$1.35M |
| 5 |
Goldman Sachs
New York
|
-$410K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$329 | +33 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | +$379 | +38 | New |
|
LBPH Hedge Fund Activity: Q2 2021 in Review
17 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q2 2021, worth a combined $71.7M — down 50% from $143M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LBPH and 5 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $1.1M. The largest seller was Citigroup, exiting entirely with an estimated $6.62M sold.
- 17 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q2 2021, down from 22 in Q1 2021.
- Funds reported $71.7M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 50% quarter-over-quarter.
- 5 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 10 closed out, a net change of -5 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $1.1M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Citigroup, an estimated $6.62M sold.
Based on aggregated 13F filings for Q2 2021.